Ask AI
Moderate to Severe Atopic Dermatitis Treatment Selection
Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: June 19, 2025

Expiration: June 18, 2026

References

  1. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Patient Groups, Global Parents for Eczema Research, National Eczema Association, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE - and Institute of Medicine - based recommendations. Ann Allergy ASthma Immunol. 2023:1-39.
  2. ADBRY (TM) (tralokinumab-ldrm) injection prescribing information. LEO Pharma Inc. Revised December 2021.
  3. CIBINQO(R) (abrocitinib) injection prescribing information. Pfizer, Inc. Revised December 2023.
  4. Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. J Drugs Dermatol. 2022;21(12):1298:1303.
  5. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-e56.
  6. DUPIXENT(R) (dupilumab) injection prescribing information. Regeneron. Revised September 2024.
  7. EBGLYSS (lebrikizumab-lbkz) injection prescribing information. Eli Lilly and Company. Revised November 2024.
  8. JAKAFI (R) (ruxolitinib) tablets prescribing information. Incyte Corporation. Revised January 2023.
  9. Kwatra SG, Lio P, Weidinger S, et al. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatol Treat. 2023;34(1):1-8.
  10. Maleki-Yazdi KA, Heen AF, Zhao IX, et a. Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review. JAMA Dermatol. doi.10.1001/jamadermatol.2022.6045.
  11. RINVOQ (R) (upadacitinib) extended-release tablets prescribing information. AbbVie Inc. Revised April 2024.
  12. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.
  13. Silverburg JI, Gooderham M, Katoh N. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;00:1-10.
  14. UK Teratology Information Service. Use of Dupilumab in Pregnancy. Version 1.0. Issued August 2024. Available at: https://uktis.org/monographs/use-of-dupilumab-in-pregnancy/. Accessed April 10, 2025.

Access to and use of this Interactive Decision Support Tool titled, “Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics ” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for managing individuals with moderate-to-severe atopic dermatitis (AD). The information provided is based on the AAD guideline recommendations and expert guidance of Daniel Butler, MD; Peter Lio, MD, FAAD; Jennifer Schoch, MD, FAAD; Benjamin Ungar, MD; and Gil Yosipovitch, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics?” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content